Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.49 |
| ▸ | RELA | Q04206 | 4/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872188 | 0.86 | KDM1A (0.45) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL29045771 | 0.85 | BTK (0.49) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL15285432 | 0.85 | NFKB1 (0.41) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL26873668 | 0.82 | EPHX2 (0.46) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL28539529 | 0.81 | GAA (0.50) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL22723924 | 0.79 | BTK (0.47) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL24643192 | 0.76 | CTSK (0.54) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL570801 | 0.75 | GAA (0.54) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL11225493 | 0.75 | HCAR2 (0.39) | NFKB1NFKB2RELA | |
| SCHEMBL9285717 | 0.75 | SMN1; SMN2 (0.44) | NFKB1NFKB2RELAGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-02-22 | — | — | US | disclosed |
| CN-115246801-A | Free base crystal form containing piperazine polycyclic derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| CN-113056454-A | Quadricyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021083246-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2021-05-06 | — | — | WO | disclosed |
| CN-111770754-A | Polycyclic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2020156312-A1 | POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-2970146-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2909201-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-9388148-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9376396-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-28 | — | — | US | disclosed |
| EP-2970146-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2909201-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014140246-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140194437-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014064038-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-01 | — | — | WO | disclosed |
| US-5567726-A | SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | MERCK, SHARP & DOHME LTD. (GB) | 1996-10-22 | — | — | US | disclosed |
| WO-1994002477-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | DRD3, DRD2, ADCY3 | NFKB1 3866/4885NFKB2 3298/4885RELA 3943/4885 |
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | TYK2, ERBB2, PTK2B | NFKB1 1896/4885NFKB2 1255/4885RELA 3009/4885 |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | DRD3, DRD2, ADCY3 | NFKB1 3866/4885NFKB2 3298/4885RELA 3943/4885 |
| US-20140194437-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | DRD3, DRD2, HTR3C | NFKB1 3778/4885NFKB2 3340/4885RELA 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.